<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00288119</url>
  </required_header>
  <id_info>
    <org_study_id>R01DK070863</org_study_id>
    <secondary_id>NIH IK24DK02800</secondary_id>
    <nct_id>NCT00288119</nct_id>
    <nct_alias>NCT00058877</nct_alias>
  </id_info>
  <brief_title>Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma</brief_title>
  <acronym>FBE</acronym>
  <official_title>Genetic and Environmental Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospitals Cleveland Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mercy Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Puget Sound Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospitals Cleveland Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objectives of this BETRNet Research Center (RC) are:

        1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in
           Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA)

        2. to increase the biological understanding of key observations made by our clinical
           researchers;

        3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to
           solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in
           order to prevent EAC and improve the outcomes of EAC;

        4. to foster a transdisciplinary and translation research culture and to effectively expand
           and enhance scientific research focused on BE and EAC;

        5. to evaluate research and transdisciplinary programs and to continuously improve
           research, productivity and enhance translational implementation. These objectives build
           and synergize on existing multi-institutional collaborative networks and the
           considerable clinical, basic science, and translational expertise available at our
           institutions, focusing on improving the outcomes of patients with BE and EAC. The
           overarching organization framework for this RC proposal is 1) to focus laboratory
           research on understanding the genetic susceptibility, genomic and epigenetic changes
           that influence the development of BE and EAC; and 2) to then translate
           laboratorydiscoveries into clinical applications for effective detection, molecular risk
           stratification, and prevention of progression from BE to EAC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research will eventually lead to the identification of inherited genetic changes that
      cause Barrett's esophagus and esophageal cancer. It will help the investigators develop
      better methods for preventing or identifying esophageal cancer at an early curable stage.

      The capsule can be swallowed with a few sips water. Once the capsule is advanced to 45-50 cm
      from the incisors and reaches the stomach the balloon is inflated to a size of 16 mm with 5.5
      cc air. It is withdrawn until a tug is felt to locate the gastroesophageal junction (GEJ).
      The inflated balloon is then pulled back 3 to 5 cm to sample the distal esophagus, then
      completely deflated to cause inversion of the biospecimen into its protective capsule, and
      then withdrawn. The balloon is re-inflated outside the patient and the obtained sample is
      clipped with scissors into a vial and frozen. The collected biospecimen will be stored frozen
      for later DNA extraction and assay. The vials will be labeled with a coded sample number. In
      a pilot study of 120 subjects this capsule esophageal sampling was performed with no adverse
      events reported. Similar esophageal sampling devices have been reported on over 1600 patients
      with no adverse events.

      All patients will also undergo standard EGD. Patients with BE or EAC will have standard of
      care surveillance and diagnostic biopsies. All cases and controls will have research
      esophageal brushings from the BE/EAC and distal esophagus/gastric cardia, respectively. Cases
      and controls will also obtain research brushings from the proximal normal squamous esophagus.
      Research mucosal biopsies will also be obtained from the BE and EAC epithelium as well as
      normal stomach and duodenum in cases and from the gastric cardia and the distal squamous
      esophagus as well as normal stomach and duodenum in controls. Biopsies from BE and EAC will
      be directed by using high definition narrow band imaging. Biospecimens, brushings and
      biopsies, will be snap frozen at bedside and stored for future research assays. Although we
      do not anticipate any problems with our non-endoscopic balloon screening, these archived
      pathology samples and snap frozen samples will be available for assay in case we fail to
      detect our markers in patients with BE diagnosed at EGD or experience a high false positive
      rate. Subjects who undergo non-endoscopic sampling of the distal esophagus will be asked
      questions that rate their discomfort on a Likert scale and also asked questions comparing the
      non-endoscopic sampling study with an EGD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2005</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assay of DNA and RNA markers</measure>
    <time_frame>1 week</time_frame>
    <description>The Balloon tip is collected and sent to the University Hospitals Translation Laboratory to test for DNA extraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Score of tolerability and acceptability</measure>
    <time_frame>1 minute after procedure</time_frame>
    <description>6 item scale rating scale using scale of 1-10 where 1 is no worries to 10 being severe to rate Tolerability; and a 3 item scale rating the acceptability of Balloon Capsule Device using strongly agree to strongly disagree rating</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Barrett's Esophagus</condition>
  <condition>Esophageal Neoplasm</condition>
  <arm_group>
    <arm_group_label>Cases</arm_group_label>
    <description>Patients with Barrett's esophagus undergoing surveillance or patients with esophageal adenocarcinoma and esophagogastric junctional adenocarcinoma undergoing EGD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EGD Screening</arm_group_label>
    <description>Patients scheduled for clinically indicated EGD for GERD who meet ACG criteria for BE screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Colon Screening</arm_group_label>
    <description>Patients scheduled for screening colonoscopy who have not had EGD and meet clinically indicated criteria for BE screening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>Patients scheduled for EGD who do not meet criteria for screening</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Balloon Capsule Device</intervention_name>
    <description>The Esophageal Sampling Device BESD-001 is a non-endoscopic balloon capsule catheter for obtaining an esophageal mucosal sample. At the distal end of the catheter there is a silicone capsule textured balloon assembly. The textured balloon is initially inverted with vacuum for patient to swallow the capsule but then is inflated with 5.6 cc of air (5 cc syringe withdrawn maximally) to a 16-18 mm diameter in order to contact the lumen of the esophagus to collect a sample. The balloon has a textured surface, which enhances the collection of the esophageal sample. Following sample collection the textured balloon is inverted back into the hollow capsule component via syringe draw vacuum in order to maximize &amp; protect the site-specific sample collection.</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Colon Screening</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>EGD Screening</arm_group_label>
    <other_name>Esophageal Sampling Device BESD-001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy</intervention_name>
    <description>An upper endoscopy is a procedure used to visually examine your upper digestive system with a tiny camera on the end of a long, flexible tube.</description>
    <arm_group_label>Cases</arm_group_label>
    <arm_group_label>Colon Screening</arm_group_label>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>EGD Screening</arm_group_label>
    <other_name>EGD</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples from + families with 3 or members diagnosed with BE or ECA will be sent to our
      NIH approved Biorepository and this repository is designed to help all researchers performing
      studies on the genetic basis of diseases.

      Biospecimens, brushings and biopsies, will be obtained via snap frozen at bedside and stored
      for future research assays at Case Western Reserve Biorepository.

      Balloon Capsule Device Tips are sent to the University Hospitals Transnational Laboratory in
      Cleveland. The tips are processed for process of assay of DNA and RNA.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with Barrett's esophagus or adenocarcenoma of the esophagus whose medical care
        is at the participating institutions, are referred from outside institutions, or who
        contact the participating institutions.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Eligible cases will be defined as those patients and their family members who meet the
        following criteria:

          -  Barrett's esophagus confirmed by review of pathology and endoscopy report or
             adenocarcinoma of the esophagus or family members of person with Barrett's esophagus
             or adenocarcinoma of the esophagus.

          -  Male or female age 18 or older at time of enrollment or male or female less than 18
             years of age at time of enrollment with parental consent.

          -  Ability to give informed consent, if patient is age 18 or older.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amitabh Chak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center, CWRU, Cleveland, OH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gary W Falk, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William Grady, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center, UWMC, Seattle, WA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas J Shaheen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ganapathy Prasad, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcia Canto, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>John Dumont, D.O.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospitals Cleveland Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Prashanthi Thota, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julian Abrams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrew Kaz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Puget Sound Health Care System</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amitabh Chak, MD</last_name>
    <phone>216-844-5385</phone>
    <email>axc22@po.cwru.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wendy Brock, RN</last_name>
    <phone>216-844-3853</phone>
    <email>wendy.brock@UHhospitals.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcia Canto, M.D.</last_name>
      <phone>410-614-5388</phone>
    </contact>
    <contact_backup>
      <last_name>Hilary Cosby, RN</last_name>
      <phone>(410) 502-2893</phone>
      <email>Hcosby1@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Marcia I Canto, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ganapathy A Prasad, M.D.</last_name>
      <phone>507-255-6930</phone>
      <email>Prasad.Ganapathy@Mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michele Johnson</last_name>
      <phone>(507) 293-5307</phone>
      <email>johnson.michele@Mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ganapathy A Prasad, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Wang, MD</last_name>
      <phone>314-362-5952</phone>
      <email>jwang@DOM.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Thomas Hollander</last_name>
      <phone>314-747-1973</phone>
      <email>tholland@DOM.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jean Wang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julian Abrams, MD</last_name>
      <phone>212-342-0476</phone>
      <email>ja660@mail.cumc.columbia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adriana Rodriquez</last_name>
      <phone>212-304-5606</phone>
    </contact_backup>
    <investigator>
      <last_name>Julian Abrams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas J Shaheen, M.D.</last_name>
      <phone>919-966-2513</phone>
      <email>nshaheen@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Bracken-Barnes</last_name>
      <phone>(919) 843-9616</phone>
      <email>catherine_bracken@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas J Shaheen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals of Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-8066</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amitabh Chak, MD</last_name>
      <phone>216-844-5386</phone>
      <email>axc22@po.cwru.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wendy Brock, RN</last_name>
      <phone>216-844-3853</phone>
      <email>wendy.brock@UHhospitals.org</email>
    </contact_backup>
    <investigator>
      <last_name>Amitabh Chak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Dumot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prashanthi Thota, MD</last_name>
      <phone>216-444-0780</phone>
      <email>THOTAP@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Hunter Block-Beach</last_name>
      <phone>(216) 442-5382</phone>
      <email>BLOCKH@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Prashanthi Thota, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gary W Falk, MD, MS</last_name>
      <phone>215-615-6588</phone>
      <email>Gary.Falk@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Maureen Demarshall, RN</last_name>
      <phone>215-349-8546</phone>
      <email>demarchm@mail.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gary W. Falk, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Puget Sound Health Care System</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Kaz, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Julie LaGuire</last_name>
      <phone>206-277-6662</phone>
      <email>julie.laguire@VA.gov</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center, UWMC</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Grady, MD</last_name>
      <phone>206-667-1107</phone>
      <email>wgrady@fhcrc.org</email>
    </contact>
    <contact_backup>
      <last_name>Wynn Burke</last_name>
      <email>WBurke@medicine.washington.edu</email>
    </contact_backup>
    <investigator>
      <last_name>William Grady, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kaz Andrew, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>February 6, 2006</study_first_submitted>
  <study_first_submitted_qc>February 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2006</study_first_posted>
  <last_update_submitted>June 28, 2018</last_update_submitted>
  <last_update_submitted_qc>June 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</investigator_affiliation>
    <investigator_full_name>Dr Amitabh Chak</investigator_full_name>
    <investigator_title>Dr. Amitabh Chak, M.D., Prinicipal Investigator Dr. Gary Falk, M.D. , MS Principal Investigator, Familial Barrett's Esophagus Consortium.</investigator_title>
  </responsible_party>
  <keyword>Barrett's Esophagus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Barrett Esophagus</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

